top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

62.86 +1.36 (+2.21%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗
The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns. 
Via The Motley Fool
Topics Intellectual Property
Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question ↗
Via Chartmill
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? ↗
As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Both have attracted considerable attention from Wall Street recently. 
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
News headline image
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector. 
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Sell BMY and 1 Stock to Buy Instead
Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d... 
Via StockStory
Topics Stocks
News headline image
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
These healthcare leaders are unlikely to suspend their dividend programs. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk. 
Via The Motley Fool
Topics ETFs
News headline image
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations. 
Via The Motley Fool
News headline image
1 Momentum Stock on Our Buy List and 2 We Turn Down
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
Via StockStory
News headline image
Are Mega-Mergers Back? ↗
Companies try to get deals done while regulators allow them. But are buyouts always a good idea? 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗
There's a good reason why AstraZeneca tanked when merger rumors hit the Street. 
Via The Motley Fool
News headline image
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗
This problem has a solution, and Pfizer is implementing it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Managemen... 
Via StockStory
Topics Earnings
News headline image
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗
Growth portfolio now drives 60% of revenue as Eliquis surges 21%. 
Via The Motley Fool
Topics Earnings
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page